



## **Overview**


- Normal Growth and Physical Development
- Anticipatory Guidance/Health Supervision
- Common Screening Tests
- Immunizations
- Child Abuse
- Common Problems in General Pediatrics
- Ethics for Primary Care


3




















 Question 1


 How soon does an infant regain birth weight?


 A. 10 to 14 days


 B. 4 to 7 days


 C. 3 to 4 days


 D. An infant should not lose weight after birth























|                                    | r Seats   | General Guidelines  |  |
|------------------------------------|---|---|--|
| Age Group<br>Infants &<br>toddlers | Type of Seat     Rear-facing—only     Rear-facing     convertible | All infants and toddlers should ride in a rear-facing seat until they reach the<br>highest weight or height allowed by the car seat's manufacturer. Most convertible<br>seats have limits that will permit children to ride rear-facing for 2 years or more.  |  |
| Toddlers &<br>preschoolers         | Convertible     Forward-facing     with harness                   | Children who have outgrown the rear-facing weight or height limit<br>for their convertible seat should use a <b>forward-facing seat</b> with a<br>harness for as long as possible, up to the highest weight or height<br>allowed by their car safety seat manufacturer.   |  |
| School-aged<br>children            | Booster seats   | All children whose weight or height exceeds the forward-facing limit<br>for their car safety seat should use a <b>belt-positioning booster</b><br><b>seat</b> until the vehicle seat belt fits properly, typically when they<br>have reached 4 feet 9 inches in height and are 8 through 12 years<br>of age. All children younger than 13 should ride in the back seat. |  |
| Older<br>children                  | Seat belts  | When children are old enough and large enough for the vehicle<br>seat belt to fit them correctly, they should always use <b>lap and</b><br><b>shoulder seat belts</b> for the best protection. All children younger<br>than 13 years should ride in the back seat.  |  |





















































| Conductive Hearing Loss  | Sensorineural Hearing Loss   |
|--|--|
| <u>Congenital</u>  |  |
| Microtia/atresia   | Genetic disorders (syndromic, connexin 26,   |
| Tympanic membrane abnormalities                                      | mitochondrial)   |
| Ossicular malformations  | In utero infections (cytomegalovirus, measles,<br>mumps, rubella, varicella, syphilis) |
|  | Anatomic abnormalities of the cochlea or temporal<br>bone                              |
|  | Exposure to ototoxic drugs during pregnancy<br>(alcohol, isotretinoin, cisplatinum)    |
|  | Hyperbilirubinemia   |
| Acquired   |  |
| Infection (acute otitis media, otitis<br>externa, ossicular erosion) | Infections (bacterial meningitis, measles, mumps,<br>rubella, Lyme disease)            |
| Otitis media with effusion   | Trauma (physical or acoustic)  |
| Foreign body (including cerumen)                                     | Radiation therapy for head and neck tumors   |
| Cholesteatoma  | Neurodegenerative or demyelinating disorders   |
| Trauma (ossicular disruption, tympanic<br>membrane perforation)      | (Alport, Cogan syndromes)  |









| л | 1 |
|---|---|
| 4 | т |


| ► B | lood Pressure (  | BP)   |   |   |   |
|-----|--|---|---|---|---|
| Ai  | nnually after 3 years  |   |   |   |   |
|     | efore age 3 years, Bl<br>ardiovascular conditi   | P should be obtained<br>ion)  | if risk is present (I                             | renal or  |   |
| SE  | everal days  |   | 5   | period of at least  |   |
| ► H | igh normal BP (90-95<br>TN is a blood pressu   |   | ercentile and age)                                |   |   |
| ► H | igh normal BP (90-95<br>TN is a blood pressur  | re over 95%   | AAP 2017 for Children                             | ≥13 y   | _ |
| ► H | igh normal BP (90-95<br>TN is a blood pressu   | re over 95%   | ercentile and age)                                |   |   |
| ► H | igh normal BP (90-95<br>TN is a blood pressur<br>AAP 2017 for Children 3<br>Classification           | re over 95%<br>1-13 y<br>SBP/DBP Percentile   | AAP 2017 for Children<br>Classification           | ≥13 y<br>Absolute Threshold                               |   |
| ► H | igh normal BP (90-95<br>TN is a blood pressur<br>AAP 2017 for Children :<br>Classification<br>Normal | re over 95%<br>1-13 y<br>SBP/DBP Percentile<br><90th<br>≥90th to <95th Or<br>120/80 mm Hg to<br><95th (whichever is | AAP 2017 for Children<br>Classification<br>Normal | ≥13 y<br>Absolute Threshold<br><120/<80mmHg<br>120/<80 to |   |





























|   | Minimum              |   | Persons aged 4 months through 6 years<br>Minimum Interval Between Doses   |  |                       |  |  |
|---|----------------------|---|---|--|-----------------------|--|--|
| Vaccine   | Age for<br>Dose 1    | Dose 1 to dose 2  |   |  |                       |  |  |
| Hepatitis B <sup>r</sup>  | Birth                | 4 weeks   | 8 weeks and at least 16 weeks after first dose; minimum age<br>for the final dose is 24 weeks   |  |                       |  |  |
| Rotavirus <sup>2</sup>  | 6 weeks              | 4 weeks   | 4 weeks   |  |                       |  |  |
| Diphtheria, tetanus, & acellular pertussis 3                          | 6 weeks              | 4 weeks   | 4 weeks   | 6 months   | 6 months <sup>2</sup> |  |  |
| Haemophilus<br>influenzee type b <sup>s</sup>                         | 6 weeks              | 4 weeks if first dose administered at younger than age<br>12 months<br>first dose administered at age 15 months<br>No further doses needed<br>if first dose administered at age 15 months or older  | 4 works/of fournet age is younger han 10 months and finat<br>8 works/or and use 12 months through 50 months data<br>8 works and use 12 months through 50 months rays final<br>4 months for a second second second second second second<br>8 months for a second second second second second second<br>1 months for a second second second second second second<br>1 months for a second second second second second second<br>1 months for a second second second second second second<br>1 months for a second second second second second second<br>1 months for a second | 8 weeks (as final dose)<br>This dose only necessary for children aged 12 through<br>58 months who received 3 (PR-P) dose before age<br>12 months and started the primary series before age<br>7 months     |                       |  |  |
| Pneumococcal <sup>s</sup>   | 6 weeks              | 4 weeks if first dose administered at younger than age<br>28 weeks (as final dose for healthy children) if first dose<br>administered at ge 12 months or older<br>No further doses needed for healthy children if first dose<br>administered at ge 24 months or older | 4 weeks if current age is younger than 12 months<br>8 weeks (as final does for healthy children) if current age is 12<br>months or older<br>No further does mended for healthy children if previous dose<br>administered at age 24 months or older  | B weeks (as final dose)<br>This dose only necessary for children aged 12 through<br>59 months who received 3 doses before age 12<br>months or for children at high risk who received 3<br>doses at any age |                       |  |  |
| Inactivated poliovirus7   | 6 weeks              | 4 weeks <sup>7</sup>  | 4 weeks <sup>7</sup>  | 6 months <sup>7</sup> minimum age 4 years for final dose   |                       |  |  |
| Meningococcal <sup>13</sup>   | 6 weeks              | 8 weeks <sup>12</sup>   | See footnote 13   | See footnote 13  |                       |  |  |
| Measles, mumps,<br>rubella <sup>9</sup>                               | 12<br>months         | 4 weeks   |   |  |                       |  |  |
| Varicella <sup>10</sup>   | 12 months            | 3 months  |   |  |                       |  |  |
| Hepatitis A <sup>#</sup>  | 12 months            | 6 months  |   |  |                       |  |  |
|   |                      |   | Persons aged 7 through 18 years   |  |                       |  |  |
| Tetanus, diphtheria;<br>tetanus, diphtheria, &<br>acellular pertussis | 7 years <sup>4</sup> | 4 weeks   | 4 weeks if first dose of DTaP/DT administered at younger than<br>age 12 months<br>6 months if first dose of DTaP/DT administered at age 12<br>months or older and then no further doses needed for catch-up   | 6 months if first dose of DTaP/DT administered at<br>younger than age 12 months  |                       |  |  |
| Human papillomavirus <sup>12</sup>                                    | 9 years              |   | Routine dosing intervals are recommended <sup>12</sup>  |  |                       |  |  |
| Hepatitis A <sup>11</sup>   | 12 months            | 6 months  |   |  |                       |  |  |
| Hepatitis B <sup>1</sup>  | Birth                | 4 weeks   | 8 weeks (and at least 16 weeks after first dose)  |  |                       |  |  |
| Inactivated poliovirus7   | 6 weeks              | 4 weeks   | 4 weeks <sup>7</sup>  | 6 months <sup>7</sup>  |                       |  |  |
| Meningococcal <sup>13</sup>   | 6 weeks              | 8 weeks <sup>12</sup>   |   |  |                       |  |  |
| Measles, mumps,<br>rubella <sup>s</sup>                               | 12 months            | 4 weeks   |   |  |                       |  |  |
| Varicella <sup>10</sup>   | 12<br>months         | 3 months if person is younger than age 13 years<br>4 weeks if person is aged 13 years or older  |   |  |                       |  |  |
| NOTE: The above   | recomme              | ndations must be read along with the foo  | otnotes of this schedule.   |  |                       |  |  |



























## MMR


- Measles-Mumps-Rubella (MMR)
- Live attenuated vaccine
- > 2 dose series given at 12-15 months and at 4-6 years
- Catch-up: 2 doses at least 4 weeks apart
- If given at <12 months old, needs to be repeated due to lack of immunogenicity
- Can be given as early as 6 months, but must be revaccinated at 12 months of age
- During an outbreak, MMR given within 72 hours of exposure to measles may provide some protection and is preferred to immune globulin





































































































| Orbital vs  | Periorbita           | al Cellulitis                 |
|---|----------------------|-------------------------------|
| Clinical features of preseptal and orbital cellulit |                      |                               |
| Clinical feature                                    | Preseptal cellulitis | Orbital cellulitis            |
| Eyelid swelling with or without erythema            | Yes                  | Yes                           |
| Eye pain/tenderness                                 | May be present       | Yes; may cause deep eye pain  |
| Pain with eye movements                             | No                   | Yes                           |
| Proptosis   | No                   | Usually, but may be<br>subtle |
| Ophthalmoplegia +/-<br>diplopia                     | No                   | May be present                |
| Vision impairment                                   | No                   | May be present*               |
| Chemosis  | Rarely present       | May be present                |
| Fever   | May be present       | Usually present               |
| Leukocytosis  | May be present       | May be present                |
|   |                      |                               |



97

